Oncology Consults: Advances in Soft-Tissue Sarcoma

PROGRAM DESCRIPTION Soft-tissue sarcomas (STSs) are a heterogeneous collection of rare tumors. As such, they can arise within any site of the body, including the extremities, trunk, retroperitoneum, and head ...

PROGRAM DESCRIPTION
Soft-tissue sarcomas (STSs) are a heterogeneous collection of rare tumors. As such, they can arise within any site of the body, including the extremities, trunk, retroperitoneum, and head and neck. There are over 50 different histological subtypes, which can make accurate diagnosis challenging. STS accounts for about 58% of all sarcomas with the remainder diagnosed as sarcomas of the bone and viscera. Outcomes for patients with STS are poor, and local recurrence and metastases are common. The development of new treatments for patients with STS has been stymied by its rarity, which has a limited the number of clinical trials, trial participants, and new agents. However, recently, 4 new therapies have been approved for treating patients with high-grade STS. This activity will explore the challenges in the current care of patients with STS and prospects for improved, more personalized therapy approaches in the future.

EDUCATIONAL OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:IDENTIFY clinical and pathological characteristics of STS and challenges of traditional treatment strategies.EVALUATE the efficacy and safety of first-line STS treatments, including recent changes to clinical practice guidelines.DESIGN a treatment plan for second-line STS therapy, incorporating newly approved agents utilized in various subtypes of STS.The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

---

Write the first review

Resource tags